nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—FDPS—jaw skeleton—amyotrophic lateral sclerosis	0.121	0.688	CbGeAlD
Ibandronate—Parathyroid disorder—Riluzole—amyotrophic lateral sclerosis	0.0769	0.0936	CcSEcCtD
Ibandronate—Panophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0363	0.0442	CcSEcCtD
Ibandronate—Stridor—Riluzole—amyotrophic lateral sclerosis	0.0272	0.0331	CcSEcCtD
Ibandronate—Circumoral paresthesia—Riluzole—amyotrophic lateral sclerosis	0.0272	0.0331	CcSEcCtD
Ibandronate—Gastrointestinal tract irritation—Riluzole—amyotrophic lateral sclerosis	0.0248	0.0302	CcSEcCtD
Ibandronate—Osteonecrosis—Riluzole—amyotrophic lateral sclerosis	0.0238	0.029	CcSEcCtD
Ibandronate—Cheilitis—Riluzole—amyotrophic lateral sclerosis	0.0208	0.0254	CcSEcCtD
Ibandronate—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.0189	0.023	CcSEcCtD
Ibandronate—Endophthalmitis—Riluzole—amyotrophic lateral sclerosis	0.0186	0.0227	CcSEcCtD
Ibandronate—Bundle branch block—Riluzole—amyotrophic lateral sclerosis	0.0176	0.0214	CcSEcCtD
Ibandronate—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.0158	0.0192	CcSEcCtD
Ibandronate—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.0158	0.0192	CcSEcCtD
Ibandronate—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.0139	0.017	CcSEcCtD
Ibandronate—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0137	0.0166	CcSEcCtD
Ibandronate—FDPS—medulla oblongata—amyotrophic lateral sclerosis	0.0118	0.0673	CbGeAlD
Ibandronate—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.011	0.0134	CcSEcCtD
Ibandronate—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0131	CcSEcCtD
Ibandronate—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.0107	0.013	CcSEcCtD
Ibandronate—FDPS—spinal cord—amyotrophic lateral sclerosis	0.0105	0.06	CbGeAlD
Ibandronate—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00988	0.012	CcSEcCtD
Ibandronate—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00974	0.0119	CcSEcCtD
Ibandronate—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00937	0.0114	CcSEcCtD
Ibandronate—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00937	0.0114	CcSEcCtD
Ibandronate—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00931	0.0113	CcSEcCtD
Ibandronate—FDPS—nervous system—amyotrophic lateral sclerosis	0.00887	0.0505	CbGeAlD
Ibandronate—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00881	0.0107	CcSEcCtD
Ibandronate—FDPS—central nervous system—amyotrophic lateral sclerosis	0.00854	0.0487	CbGeAlD
Ibandronate—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00846	0.0103	CcSEcCtD
Ibandronate—FDPS—cerebellum—amyotrophic lateral sclerosis	0.00835	0.0476	CbGeAlD
Ibandronate—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00801	0.00976	CcSEcCtD
Ibandronate—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00789	0.0096	CcSEcCtD
Ibandronate—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00777	0.00946	CcSEcCtD
Ibandronate—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00719	0.00876	CcSEcCtD
Ibandronate—Injury—Riluzole—amyotrophic lateral sclerosis	0.007	0.00852	CcSEcCtD
Ibandronate—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00685	0.00834	CcSEcCtD
Ibandronate—FDPS—brain—amyotrophic lateral sclerosis	0.00678	0.0386	CbGeAlD
Ibandronate—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00676	0.00823	CcSEcCtD
Ibandronate—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00662	0.00806	CcSEcCtD
Ibandronate—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00643	0.00783	CcSEcCtD
Ibandronate—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00633	0.00771	CcSEcCtD
Ibandronate—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00621	0.00756	CcSEcCtD
Ibandronate—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00612	0.00745	CcSEcCtD
Ibandronate—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00581	0.00708	CcSEcCtD
Ibandronate—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00569	0.00693	CcSEcCtD
Ibandronate—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00556	0.00677	CcSEcCtD
Ibandronate—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00556	0.00677	CcSEcCtD
Ibandronate—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00556	0.00677	CcSEcCtD
Ibandronate—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00535	0.00651	CcSEcCtD
Ibandronate—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00533	0.00649	CcSEcCtD
Ibandronate—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00503	0.00612	CcSEcCtD
Ibandronate—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00498	0.00607	CcSEcCtD
Ibandronate—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00496	0.00604	CcSEcCtD
Ibandronate—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00496	0.00604	CcSEcCtD
Ibandronate—Depression—Riluzole—amyotrophic lateral sclerosis	0.00494	0.00602	CcSEcCtD
Ibandronate—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00483	0.00588	CcSEcCtD
Ibandronate—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00482	0.00587	CcSEcCtD
Ibandronate—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00475	0.00579	CcSEcCtD
Ibandronate—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00469	0.00571	CcSEcCtD
Ibandronate—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00447	0.00545	CcSEcCtD
Ibandronate—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00445	0.00542	CcSEcCtD
Ibandronate—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00442	0.00538	CcSEcCtD
Ibandronate—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00439	0.00535	CcSEcCtD
Ibandronate—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00438	0.00534	CcSEcCtD
Ibandronate—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00437	0.00532	CcSEcCtD
Ibandronate—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00436	0.00531	CcSEcCtD
Ibandronate—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00506	CcSEcCtD
Ibandronate—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00413	0.00503	CcSEcCtD
Ibandronate—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00404	0.00492	CcSEcCtD
Ibandronate—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00402	0.00489	CcSEcCtD
Ibandronate—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00488	CcSEcCtD
Ibandronate—Chills—Riluzole—amyotrophic lateral sclerosis	0.00399	0.00486	CcSEcCtD
Ibandronate—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00393	0.00479	CcSEcCtD
Ibandronate—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.0039	0.00475	CcSEcCtD
Ibandronate—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00387	0.00472	CcSEcCtD
Ibandronate—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00382	0.00465	CcSEcCtD
Ibandronate—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00462	CcSEcCtD
Ibandronate—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00375	0.00456	CcSEcCtD
Ibandronate—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00453	CcSEcCtD
Ibandronate—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00438	CcSEcCtD
Ibandronate—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00358	0.00436	CcSEcCtD
Ibandronate—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00354	0.00431	CcSEcCtD
Ibandronate—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00349	0.00425	CcSEcCtD
Ibandronate—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00348	0.00424	CcSEcCtD
Ibandronate—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00417	CcSEcCtD
Ibandronate—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00334	0.00407	CcSEcCtD
Ibandronate—Risedronate—PTGS2—amyotrophic lateral sclerosis	0.00333	1	CrCbGaD
Ibandronate—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00402	CcSEcCtD
Ibandronate—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00402	CcSEcCtD
Ibandronate—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.0033	0.00402	CcSEcCtD
Ibandronate—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00329	0.004	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00327	0.00399	CcSEcCtD
Ibandronate—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00326	0.00397	CcSEcCtD
Ibandronate—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00322	0.00393	CcSEcCtD
Ibandronate—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00385	CcSEcCtD
Ibandronate—Infection—Riluzole—amyotrophic lateral sclerosis	0.00314	0.00382	CcSEcCtD
Ibandronate—Shock—Riluzole—amyotrophic lateral sclerosis	0.00311	0.00379	CcSEcCtD
Ibandronate—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.0031	0.00378	CcSEcCtD
Ibandronate—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00307	0.00374	CcSEcCtD
Ibandronate—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00306	0.00372	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00288	0.00351	CcSEcCtD
Ibandronate—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00286	0.00348	CcSEcCtD
Ibandronate—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00284	0.00346	CcSEcCtD
Ibandronate—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00339	CcSEcCtD
Ibandronate—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00275	0.00335	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00332	CcSEcCtD
Ibandronate—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00273	0.00332	CcSEcCtD
Ibandronate—Pain—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00329	CcSEcCtD
Ibandronate—Constipation—Riluzole—amyotrophic lateral sclerosis	0.0027	0.00329	CcSEcCtD
Ibandronate—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00317	CcSEcCtD
Ibandronate—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00315	CcSEcCtD
Ibandronate—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00251	0.00306	CcSEcCtD
Ibandronate—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00304	CcSEcCtD
Ibandronate—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00304	CcSEcCtD
Ibandronate—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00284	CcSEcCtD
Ibandronate—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00276	CcSEcCtD
Ibandronate—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00272	CcSEcCtD
Ibandronate—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00263	CcSEcCtD
Ibandronate—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00255	CcSEcCtD
Ibandronate—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00201	0.00245	CcSEcCtD
Ibandronate—Rash—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00243	CcSEcCtD
Ibandronate—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00243	CcSEcCtD
Ibandronate—Headache—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00241	CcSEcCtD
Ibandronate—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00188	0.00229	CcSEcCtD
